BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naranjo Muñoz J, Garcia Garcia-doncel A, Montero Escobar ME, Villanego Fernandez F, Millán Ortega I, Ceballos Guerrero M. Eculizumab en el síndrome hemolítico urémico atípico. ¿Hasta cuándo mantenerlo? Nefrología 2019;39:440-2. [DOI: 10.1016/j.nefro.2019.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Ubetagoyena Arrieta M, Montes Medina L, Pérez Sukia L. Bilateral hip osteonecrosis and cholelithiasis after eculizumab discontinuation in atypical hemolytic uremic syndrome. Nefrologia 2021:S0211-6995(21)00139-9. [PMID: 34376310 DOI: 10.1016/j.nefro.2021.03.011] [Reference Citation Analysis]